CAS NO: | 2752-65-0 |
规格: | ≥98% |
包装 | 价格(元) |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 628.75 |
---|---|
Formula | C38H44O8 |
CAS No. | 2752-65-0 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 100 mg/mL (159.04 mM) |
Water:<1 mg/mL (slightly soluble or insoluble) | |
Ethanol: N/A | |
Synonyms | ss-Guttiferrin; ss-Guttiferrin; ss-Guttilactone; Cambogic acid; Guttatic acid; Guttic acid. |
Other info | Chemical Name: (Z)-4-((1S,3aR,5S,11R,14aS)-8-hydroxy-2,2,11-trimethyl-13-(3-methylbut-2-en-1-yl)-11-(4-methylpent-3-en-1-yl)-4,7-dioxo-2,3a,4,5,7,11-hexahydro-1H-1,5-methanofuro[3,2-g]pyrano[3,2-b]xanthen-3a-yl)-2-methylbut-2-enoic acid InChi Key: GEZHEQNLKAOMCA-RRZNCOCZSA-N InChi Code: InChI=1S/C38H44O8/c1-20(2)10-9-15-36(8)16-14-24-29(39)28-30(40)26-18-23-19-27-35(6,7)46-37(33(23)41,17-13-22(5)34(42)43)38(26,27)45-32(28)25(31(24)44-36)12-11-21(3)4/h10-11,13-14,16,18,23,27,39H,9,12,15,17,19H2,1-8H3,(H,42,43)/b22-13-/t23-,27+,36-,37+,38-/m1/s1 SMILES Code: O=C(O)/C(C)=C\C[C@@](C([C@]1([H])C=C23)=O)(OC(C)(C)[C@]4([H])C1)[C@@]24OC5=C(C(O)=C(C=C[C@](CC/C=C(C)/C)(C)O6)C6=C5C/C=C(C)\C)C3=O |
In Vitro | Gambogic Acid is a caged xanthone that is derived from Garcinia hanburyi and functions as a strong apoptotic inducer in many types of cancer cells by inhibiting human Bcl-2 family proteins and activating caspases. Gambogic Acid also blocks Kir2.1 channels with EC50 of ≤ 100 nM. Gambogic Acid significantly inhibits human umbilical vein endothelial cell (HUVEC) proliferation, migration, invasion, tube formation, and micro-vessel growth at nM concentration. |
---|---|
In Vivo | Gambogic Acid effectively inhibits tumor angiogenesis and suppressed tumor growth with low side effects using metronomic chemotherapy with Gambogic Acid. The results indicated that iv injection of GGA 2, 4, and 8 mg/kg inhibited dramatically the growth of human hepatocellular cell line SMMC-7721 in nude mice from the early administration. |
Animal model | BALB/c nude mice bearing SMMC-7721 xenografts |
Formulation & Dosage | Intravenous injection, 2, 4, and 8 mg/kg, 3 times per week |
References | Acta Pharmacologica Sinica, 2004, 25: 769-774. |
Gambogic acid inhibits binding of FITC-BH3 peptide to anti-apoptotic Bcl-2 family proteins. Mol Cancer Ther. 2008 Jun;7(6):1639-46. |
| |